MedTrace Logo

[14C] Study to Investigate the Mass Balance and Biotransformation of WPV01 in Healthy Adult Chinese Male Participants

NCT07080658 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-07-23

No results posted yet for this study

Summary

This is a single-center, non-randomized, open-label, single-dose, Phase I clinical study to evaluate the mass balance and biotransformation, safety and tolerability of WPV01 in healthy adult chinese male participants following a single oral administration of \[14C\] WPV01.

Conditions

Interventions

DRUG

[14C]-WPV01

Single oral dose of 600 mg \[14C\]-WPV01

Sponsors & Collaborators

  • Westlake Pharmaceuticals (Hangzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Wei Zhao · Qianfoshan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-23
Primary Completion
2023-07-24
Completion
2023-08-06

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07080658 on ClinicalTrials.gov